- Market Capitalization, $K 360,764
- Shares Outstanding, K 313,708
- Annual Sales, $ 62,440 K
- Annual Income, $ -103,090 K
- 60-Month Beta 0.36
- Price/Sales 5.73
- Price/Cash Flow N/A
- Price/Book 0.89
|Period||Period Low||Period High||Performance|
| || |
-0.1900 (-13.57%)since 04/26/22
| || |
-0.2800 (-18.79%)since 02/25/22
| || |
-1.6100 (-57.09%)since 05/26/21
The cannabis industry has attracted significant investor attention over the past couple of years due to its growing use for both medical and recreational purposes. Also, the increasing legalization of...
As the cannabis market awaits a Senate vote on a legalization bill, these companies may not need it to succeed with investors
Cannabis investors aren't normally used to this much good news.
In a competitive market, this little gem might seal the deal
Investors saw progress in the company's second-quarter earnings.
Over the last few weeks, the U.S. House passed a bill that could pave the way for legalizing cannabis at the federal level. In fact, “the bill, which was sponsored by New York Representative Jerry Nadler,...
OrganiGram (NASDAQ: OGI) reached a turning point in Q1 in which profitability became truly in reach. The company updated its outlook for profitability from Q4 to Q3 of the current fiscal year and the outlook...
A 117% year-over-year jump in net revenue caught investors' attention.
At the moment, CBN, or cannabinol is soaring in popularity. That could be significant news for companies, like Xebra Brands (CSE: XBRA) (OTCQB: XBRAF), which is launching one of the only beverages in...
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.15%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?
|3rd Resistance Point||1.2233|
|2nd Resistance Point||1.1967|
|1st Resistance Point||1.1733|
|1st Support Level||1.1233|
|2nd Support Level||1.0967|
|3rd Support Level||1.0733|